Over the past five years, ICER has pressured drugmakers to lower the cost of nearly 100 drugs.
This infographic sourced via Reuters illustrates the growing power of the Boston-based nonprofit on holding down drug prices in the United States. ICER was founded in 2006 with the aim of providing a non binding evaluation of new health technologies (including drugs), in hopes of aligning it with the aim of an agency such as NICE in the UK.
Over the past five years, ICER has pressured drugmakers to lower the cost of nearly 100 drugs. It aims to play a similar role with emerging COVID-19 treatments and vaccines.
Most recently in the U.S., over the pricing of COVID-19 treatment, Remdisivir. Wall Street investors bet on estimates that its maker, Gilead Sciences, could charge up to $10,000 for the treatment. However, Gilead announced it would charge about $3,100 for a five-day treatment and $5,700 for ten days - in line with the ICER recommendation.